title: Cognitive efficacy of quetiapine and olanzapine in early-onset first-episode psychosis.
abstract: The primary purpose of this study was to compare changes in cognition in early-onset psychosis after 6-months treatment with quetiapine or olanzapine. This is a randomized, single-blind, 6-month study in 50 adolescents with a diagnosis of early-onset psychosis. Patients were randomized to quetiapine (n = 24) or olanzapine (n =26). A thorough neuropsychological battery was administered at baseline and after 6-month treatment. Out of the total sample included in the study, 32 patients completed at least 6-months treatment with the assigned medication (quetiapine, n =16; olanzapine, n = 16). No changes were observed in cognitive performance after 6-month treatment with quetiapine or olanzapine. Although some trends toward cognitive improvement were observed for the olanzapine group after 6-month treatment, neither group showed statistically significant gains. Furthermore, there was no evidence of any differential efficacy of olanzapine or quetiapine on cognitive improvement in this sample of adolescents with psychosis.
authors.affiliation: Adolescent Unit, Psychiatry Department, Hospital General Universitario Gregorio Marañón, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain.
authors.forename: Olalla
authors.initials: O
authors.lastname: Robles
authors.forename: Arantzazu
authors.initials: A
authors.lastname: Zabala
authors.forename: Igor
authors.initials: I
authors.lastname: Bombín
authors.forename: Mara
authors.initials: M
authors.lastname: Parellada
authors.forename: Dolores
authors.initials: D
authors.lastname: Moreno
authors.forename: Ana
authors.initials: A
authors.lastname: Ruiz-Sancho
authors.forename: Celso
authors.initials: C
authors.lastname: Arango
mesh_terms: D000293:Adolescent; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D003987:Dibenzothiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests / Q000706:statistics & numerical data*; D000077152:Olanzapine; D011594:Psychometrics; D011618:Psychotic Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D000069348:Quetiapine Fumarate; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D016037:Single-Blind Method; D013030:Spain; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D000077152:Olanzapine
references.citation: J Abnorm Psychol. 1989 Nov;98(4):367-80
references.pmid: 2574202
references.citation: Schizophr Res. 2001 Mar 1;48(1):17-28
references.pmid: 11278151
references.citation: Am J Psychiatry. 1996 Mar;153(3):321-30
references.pmid: 8610818
references.citation: Am J Psychiatry. 2009 Jun;166(6):675-82
references.pmid: 19369319
references.citation: Schizophr Res. 2002 Jan 1;53(1-2):7-16
references.pmid: 11728833
references.citation: Schizophr Bull. 1998;24(1):147-52
references.pmid: 9502552
references.citation: Schizophr Res. 2000 Apr 7;42(2):135-44
references.pmid: 10742651
references.citation: Biol Psychiatry. 1998 Sep 15;44(6):488-92
references.pmid: 9777181
references.citation: Schizophr Bull. 2005 Jan;31(1):5-19
references.pmid: 15888422
references.citation: Biol Psychiatry. 1984 May;19(5):745-53
references.pmid: 6733182
references.citation: Arch Gen Psychiatry. 2007 Jun;64(6):633-47
references.pmid: 17548746
references.citation: Am J Psychiatry. 1999 Sep;156(9):1358-66
references.pmid: 10484945
references.citation: Neuropsychology. 1998 Jul;12(3):426-45
references.pmid: 9673998
references.citation: J Psychiatry Neurosci. 2001 Mar;26(2):137-49
references.pmid: 11291531
references.citation: Arch Gen Psychiatry. 2007 Oct;64(10):1115-22
references.pmid: 17909123
references.citation: Eur Neuropsychopharmacol. 2004 Nov;14 Suppl 4:S471-9
references.pmid: 15572266
references.citation: Schizophr Bull. 1994;20(1):31-46
references.pmid: 8197420
references.citation: Schizophr Res. 2002 Oct 1;57(2-3):209-19
references.pmid: 12223252
references.citation: Neuropsychopharmacology. 2004 Jan;29(1):133-45
references.pmid: 14583740
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2005 Feb;29(2):233-8
references.pmid: 15694229
references.citation: Schizophr Bull. 1990;16(3):477-99
references.pmid: 1981108
references.citation: Biol Psychiatry. 2005 Nov 1;58(9):705-12
references.pmid: 16023084
references.citation: Schizophr Res. 2000 Dec 15;46(2-3):81-9
references.pmid: 11120419
references.citation: Arch Gen Psychiatry. 1991 Jul;48(7):618-24
references.pmid: 2069492
references.citation: Schizophr Res. 1999 Mar 1;35 Suppl:S51-60
references.pmid: 10190225
references.citation: Biol Psychiatry. 2002 Jun 15;51(12):969-71
references.pmid: 12062880
references.citation: Psychiatry Res. 2004 Dec 15;129(2):159-69
references.pmid: 15590043
references.citation: J Clin Psychopharmacol. 1998 Apr;18(2 Suppl 1):12S-9S
references.pmid: 9555611
references.citation: Schizophr Bull. 2006 Oct;32(4):666-78
references.pmid: 16829550
references.citation: Am J Psychiatry. 2005 Oct;162(10):1888-95
references.pmid: 16199835
references.citation: Encephale. 2006 May-Jun;32(3 Pt 1):341-50
references.pmid: 16840928
references.citation: Schizophr Res. 2005 Oct 1;78(1):35-43
references.pmid: 15978781
references.citation: Schizophr Res. 2004 May 1;68(1):49-63
references.pmid: 15037339
references.citation: Am J Psychiatry. 1999 Sep;156(9):1328-35
references.pmid: 10484941
references.citation: Am J Psychiatry. 2001 Feb;158(2):176-84
references.pmid: 11156796
references.citation: Schizophr Bull. 2005 Jul;31(3):705-22
references.pmid: 16006592
references.citation: Schizophr Bull. 1994;20(4):599-617
references.pmid: 7701271
references.citation: Eur Child Adolesc Psychiatry. 2009 Jul;18(7):418-28
references.pmid: 19198920
references.citation: Am J Psychiatry. 2000 Apr;157(4):514-20
references.pmid: 10739409
references.citation: Schizophr Res. 2002 Jan 15;53(3):239-48
references.pmid: 11738537
references.citation: Biol Psychiatry. 2004 Sep 1;56(5):301-7
references.pmid: 15336511
references.citation: Arch Gen Psychiatry. 1997 Feb;54(2):159-65
references.pmid: 9040284
references.citation: Eur Psychiatry. 2005 Aug;20(5-6):395-402
references.pmid: 16171654
references.citation: Schizophr Res. 2006 Jan 1;81(1):29-39
references.pmid: 16263246
references.citation: J Clin Psychopharmacol. 2003 Aug;23(4):400-4
references.pmid: 12920417
references.citation: Schizophr Bull. 1999;25(2):201-22
references.pmid: 10416727
references.citation: Schizophr Res. 2004 May 1;68(1):21-6
references.pmid: 15037336
references.citation: J Clin Psychiatry. 2006 Oct;67(10):e12
references.pmid: 17107235
references.citation: Biol Psychiatry. 1994 Dec 1;36(11):717-25
references.pmid: 7858067
references.citation: Eur Neuropsychopharmacol. 2005 Oct;15(5):525-31
references.pmid: 16139171
references.citation: Br J Psychiatry. 1990 Dec;157:799-811
references.pmid: 1981157
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2005 Feb;29(2):219-32
references.pmid: 15694228
references.citation: Arch Gen Psychiatry. 2000 Mar;57(3):249-58
references.pmid: 10711911